Coherus BioSciences, Inc. (CHRS)
After hours:
| Previous Close | 1.9300 |
| Open | 1.9400 |
| Bid | 2.0200 x 600 |
| Ask | 2.0500 x 400 |
| Day's Range | 1.9300 - 2.0600 |
| 52 Week Range | 1.4300 - 8.2200 |
| Volume | |
| Avg. Volume | 2,689,426 |
| Market Cap | 231.536M |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5300 |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.43 |
GlobeNewswireCoherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago. Presentation Details Abstract: 2664Title: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114
Simply Wall St.Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
- GlobeNewswire
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion –– Mechanism may enhance antitumor responses with immunotherapy –– First novel immuno-oncology product candidate discovered and developed by Coherus –– The CHS-1000 IND submission is planned for Q2 2024 – REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq
